Literature DB >> 16288282

Host-reactive CD8+ memory stem cells in graft-versus-host disease.

Yi Zhang1, Gerard Joe, Elizabeth Hexner, Jiang Zhu, Stephen G Emerson.   

Abstract

Graft-versus-host disease (GVHD) is caused by alloreactive donor T cells that trigger host tissue injury. GVHD develops over weeks or months, but how this immune response is maintained over time is unknown. In mouse models of human GVHD, we identify a new subset of postmitotic CD44(lo)CD62L(hi)CD8(+) T cells that generate and sustain all allogeneic T-cell subsets in GVHD reactions, including central memory, effector memory and effector CD8(+) T cells, while self-renewing. These cells express Sca-1, CD122 and Bcl-2, and induce GVHD upon transfer into secondary recipients. The postmitotic CD44(lo)CD62L(hi)CD8(+) T cells persist throughout the course of GVHD, are generated in the initial phase in response to alloantigens and dendritic cells and require interleukin-15. Thus, their long life, ability to self-renew and multipotentiality define these cells as candidate memory stem cells. Memory stem cells will be important targets for understanding and influencing diverse chronic immune reactions, including GVHD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288282     DOI: 10.1038/nm1326

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  174 in total

Review 1.  Molecular regulation of effector and memory T cell differentiation.

Authors:  John T Chang; E John Wherry; Ananda W Goldrath
Journal:  Nat Immunol       Date:  2014-12       Impact factor: 25.606

Review 2.  Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy.

Authors:  Luca Gattinoni; Yun Ji; Nicholas P Restifo
Journal:  Clin Cancer Res       Date:  2010-08-05       Impact factor: 12.531

3.  Pharmacologic induction of CD8+ T cell memory: better living through chemistry.

Authors:  Luca Gattinoni; Christopher A Klebanoff; Nicholas P Restifo
Journal:  Sci Transl Med       Date:  2009-12-16       Impact factor: 17.956

Review 4.  Therapeutic cancer vaccines: are we there yet?

Authors:  Christopher A Klebanoff; Nicolas Acquavella; Zhiya Yu; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 5.  Histone methyltransferase and histone methylation in inflammatory T-cell responses.

Authors:  Shan He; Qing Tong; Dennis Keith Bishop; Yi Zhang
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

Review 6.  Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

7.  CD4(+) CD44(v.low) cells are unique peripheral precursors that are distinct from recent thymic emigrants and stem cell-like memory cells.

Authors:  Chunfang Zhao; Idania Marrero; Aditi Narsale; Rosita Moya; Joanna D Davies
Journal:  Cell Immunol       Date:  2015-04-17       Impact factor: 4.868

8.  CD4+ memory stem cells are infected by HIV-1 in a manner regulated in part by SAMHD1 expression.

Authors:  Caroline O Tabler; Mark B Lucera; Aiman A Haqqani; David J McDonald; Stephen A Migueles; Mark Connors; John C Tilton
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 9.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

10.  Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells.

Authors:  Enrico Lugli; Luca Gattinoni; Alessandra Roberto; Domenico Mavilio; David A Price; Nicholas P Restifo; Mario Roederer
Journal:  Nat Protoc       Date:  2012-12-06       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.